GSK (NYSE:GSK) Stock Jumps 3.5% – Here’s Why

Shares of GSK PLC Sponsored ADR (NYSE:GSK) rose 3.5% on Wednesday. The company traded as high as $47.87 and last traded at $47.8950. 3,048,071 shares changed hands during mid-day trading, a decline of 32% from the average daily volume of 4,460,884 shares. The stock had previously closed at $46.27.

GSK News Roundup

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK and Oxford University dosed the first patient in a clinical trial evaluating a potential treatment for ulcerative colitis. The program expands GSK’s immunology pipeline, although the trial is at an early stage and offers no near-term revenue impact. First Patient Dosed in GSK-Oxford Colitis Trial
• Positive Sentiment: GSK plans to invest approximately $800 million to demolish and rebuild its Upper Merion, Pennsylvania, facility. The expansion should strengthen U.S. manufacturing capacity and may support the company’s long-term supply and operational strategy. GSK to invest $800M in Pennsylvania expansion
• Neutral Sentiment: RBC expects GSK’s third-quarter results to be broadly in line with expectations. Strength in HIV medicines and respiratory treatment Nucala is expected to offset weaker vaccine sales; RBC maintained its Sector Perform rating and 1,975p price target ahead of the October 28 earnings release. GSK third quarter outlook from RBC
• Negative Sentiment: GSK is reportedly planning to eliminate up to 1,217 jobs in Belgium, primarily affecting its vaccine operations. The cuts could eventually reduce costs, but the scale of the restructuring raises concerns about near-term disruption and reflects pressure on vaccine demand. GSK to cut up to 1,217 jobs in Belgium

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on GSK shares. Barclays restated a “sell” rating on shares of GSK in a research report on Monday, September 7th. Morgan Stanley reaffirmed an “underweight” rating on shares of GSK in a report on Tuesday, August 25th. Weiss Ratings cut GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. Citigroup began coverage on GSK in a research note on Friday, July 24th. They issued a “neutral” rating for the company. Finally, Royal Bank Of Canada initiated coverage on GSK in a research report on Tuesday, September 8th. They set a “sector perform” rating for the company. Four analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $55.33.

GSK Price Performance

The business has a 50-day moving average of $49.82 and a 200 day moving average of $51.73. The firm has a market capitalization of $96.82 billion, a PE ratio of 14.96, a price-to-earnings-growth ratio of 2.11 and a beta of 0.33. The company has a current ratio of 0.82, a quick ratio of 0.52 and a debt-to-equity ratio of 0.81.

GSK (NYSE:GSK) last released its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The business had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.02 billion. During the same period in the previous year, the company earned $0.47 earnings per share. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, research analysts anticipate that GSK PLC Sponsored ADR will post 4.78 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, October 8th. Shareholders of record on Friday, August 14th were paid a $0.4515 dividend. The ex-dividend date was Friday, August 14th. This is a positive change from GSK’s previous quarterly dividend of $0.44. This represents a $1.81 dividend on an annualized basis and a yield of 3.8%. GSK’s dividend payout ratio is presently 55.31%.

Institutional Trading of GSK

A number of institutional investors have recently modified their holdings of GSK. NewEdge Advisors LLC grew its position in shares of GSK by 842.9% during the 2nd quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock valued at $49,986,000 after purchasing an additional 852,437 shares in the last quarter. Sound Income Strategies LLC grew its stake in shares of GSK by 2.7% during the third quarter. Sound Income Strategies LLC now owns 348,273 shares of the pharmaceutical company’s stock valued at $16,209,000 after buying an additional 9,218 shares during the last quarter. Waverly Advisors LLC boosted its stake in shares of GSK by 1,372.8% during the second quarter. Waverly Advisors LLC now owns 290,593 shares of the pharmaceutical company’s stock valued at $15,233,000 after purchasing an additional 270,863 shares during the period. Tidal Investments LLC boosted its position in GSK by 4.6% during the 2nd quarter. Tidal Investments LLC now owns 220,236 shares of the pharmaceutical company’s stock valued at $11,545,000 after buying an additional 9,603 shares during the period. Finally, Keystone Financial Planning Inc. grew its stake in shares of GSK by 3,114.8% in the second quarter. Keystone Financial Planning Inc. now owns 195,590 shares of the pharmaceutical company’s stock worth $10,253,000 after purchasing an additional 189,506 shares during the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Company Profile

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies.

GSK’s portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions.